{
    "doi": "https://doi.org/10.1182/blood.V126.23.3142.3142",
    "article_title": "An International Multicenter Comparative Analysis of Tacrolimus Plus Sirolimus with or without Antithymocyte Globulin As Graft-Versus-Host Disease Prophylaxis in HLA-Mismatched Allogeneic Hematopoietic Cell Transplantation ",
    "article_date": "December 3, 2015",
    "session_type": "722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II",
    "abstract_text": "Background: There is lack of consensus in regards to the optimal regimen for graft-versus-host disease (GVHD) prophylaxis in patients undergoing HLA-mismatched unrelated donor (MMUD) allografting. A regimen combining tacrolimus plus sirolimus (TAC-SIR) has been shown to be effective as GVHD prophylaxis in HLA-matched related (MRD) or matched-unrelated donor (MUD) allogeneic hematopoietic cell transplantation (HCT). Addition of antithymocyte globulin (ATG) has been shown to reduce incidence of acute GVHD but it is associated with a high rate of infectious complications. Here, we retrospectively compare post-transplant outcomes using TAC-SIR or TAC-SIR-ATG in 104 patients who underwent a MMUD allogeneic HCT between June 2008 and December 2014 at 5 Spanish and 1 transplant center (MCC) in the United States. Patients and methods: Forty-three (MCC=5, Spanish Centers=38) patients received TAC-SIR whereas 61(MCC=41, Spanish Centers=20) received TAC-SIR-ATG as GVHD prophylaxis for MMUD allogeneic HCT. Patient-, disease-, and transplant characteristics are summarized in Table 1. Results : The median follow-up (months) for all, TAC-SIR, and TAC-SIR-ATG patients were 29 (5-83), 27 (5-64), and 30 (6-83) months, respectively. Patients receiving TAC-SIR had faster platelets (12 vs. 15 days, p=0.005) but slightly slower neutrophil engraftment (16 vs. 15 days, p=0.037). Addition of ATG resulted in a lower incidence of acute GVHD (grade 2-4) (44% (95%CI=33-59%) vs. 67% (95%CI=55-83%), p=0.055) and over two-fold lower incidence, albeit not statistically significant, of moderate/severe chronic GVHD (17% (95%CI=10-30%) vs. 38% (95%CI=25-60%), p=0.086). Non-relapse mortality (NRM) (2-year) was two-fold higher, but not statistically significant, in the TAC-SIR-ATG group (TAC-SIR-ATG=35% (95%CI=24-50%) vs. TAC-SIR=17% (95%CI=10-35%), p=0.078) mainly attributable to a 3-fold higher number of non-relapse deaths attributed to infections (9 vs. 3). There was no difference in cumulative incidence of relapse (2-year) (TAC-SIR=28% (95%CI=17-46%) vs. TAC-SIR-ATG=26% (95%CI=17-41%), p=0.858) or in 2-year OS (TAC-SIR=56% (95%CI=40-72%) vs. TAC-SIR-ATG=47% (95%CI=34-60%), p=0.244) between the groups. These and other outcomes are summarized in Table 2. Conclusion : In MMUD allogeneic HCT, addition of ATG to TAC-SIR results in a lower incidence of grade 2-4 acute GVHD but does not improve OS. The two-fold higher 2-year NRM with addition of ATG is probably explained by a higher incidence of resulting infectious complications with in vivo T-cell depletion. While these results are intriguing, a prospective randomized study is certainly needed to confirm these findings. Table 1. Patient-, disease-, and transplant-related characteristics.  Variables . Categories . TAC-SIR . TAC-SIR-ATG . . . MCC (N=5) . Spanish Centers (N=38) . MCC (N=41) . Spanish Centers (N=20) . Median age (range), years  53 (25-64) 51 (17-69) 52 (24-67) 55 (30-68) Gender mismatch (Donor\u2192recipient) F\u2192M F\u2192F M\u2192M,F Missing 1 1 3 0 7 5 25 1 10 13 18 0 2 0 10 8 HLA-mismatch A B C DRB1 Missing 1 1 3 0 0 10 14 8 6 0 24 13 4 0 0 8 3 3 5 1 Diagnoses ALL AML CLL CML HL MDS MF MM NHL Other 1 2 0 0 0 1 0 0 1 0 3 10 3 1 3 7 1 1 10 0 4 18 3 2 1 5 1 0 7 0 1 6 1 0 1 3 0 1 5 2 Preparative regimen FLU-BU FLU-MEL 3 2 18 20 35 6 11 7 CIBMTR risk None Low Intermediate High 0 2 1 2 0 24 2 12 1 13 15 12 0 18 2 0 Cell source BM PBSC 0 5 8 30 0 41 1 19 Median CD34 cells (range) x10 6 /recipient Kg body weight  7.99 (4.08-10.0) 6 (1.2-11.0) 8.57 (2.81-23.01) 6.08 (0.67-9.5) Recipient/donor CMV serologic status +/+ +/- -/- -/+ Missing 1 2 2 0 0 18 16 2 2 0 18 14 7 2 0 7 6 0 0 7 Variables . Categories . TAC-SIR . TAC-SIR-ATG . . . MCC (N=5) . Spanish Centers (N=38) . MCC (N=41) . Spanish Centers (N=20) . Median age (range), years  53 (25-64) 51 (17-69) 52 (24-67) 55 (30-68) Gender mismatch (Donor\u2192recipient) F\u2192M F\u2192F M\u2192M,F Missing 1 1 3 0 7 5 25 1 10 13 18 0 2 0 10 8 HLA-mismatch A B C DRB1 Missing 1 1 3 0 0 10 14 8 6 0 24 13 4 0 0 8 3 3 5 1 Diagnoses ALL AML CLL CML HL MDS MF MM NHL Other 1 2 0 0 0 1 0 0 1 0 3 10 3 1 3 7 1 1 10 0 4 18 3 2 1 5 1 0 7 0 1 6 1 0 1 3 0 1 5 2 Preparative regimen FLU-BU FLU-MEL 3 2 18 20 35 6 11 7 CIBMTR risk None Low Intermediate High 0 2 1 2 0 24 2 12 1 13 15 12 0 18 2 0 Cell source BM PBSC 0 5 8 30 0 41 1 19 Median CD34 cells (range) x10 6 /recipient Kg body weight  7.99 (4.08-10.0) 6 (1.2-11.0) 8.57 (2.81-23.01) 6.08 (0.67-9.5) Recipient/donor CMV serologic status +/+ +/- -/- -/+ Missing 1 2 2 0 0 18 16 2 2 0 18 14 7 2 0 7 6 0 0 7 View Large Table 2. Post-transplant outcomes.  Outcomes . TAC-SIR . TAC-SIR-ATG . P-value . Median days (range) to ANC>500/\u00b5L 16 (10-29) 15 (9-24) 0.037 Median days (range) to platelets engraftment 12 (6-26) 15 (0-50) 0.005 Cum incidence acute GVHD (grade 2-4) (at 100 day) 67% (55-83%) 44% (33-59%) 0.055 Cum incidence acute GVHD (grade 3-4) (at 100-day) 16% (8-32%) 10% (5-21%) 0.347 Chronic moderate or severe (at 2-year) 38% (25-60%) 17% (10-30%) 0.086 Cum incidence of NRM (at 100-day) 12% (5-27%) 13% (7-25%) 0.078 Cum incidence of NRM (2-year) 17% (10-35%) 35% (24-50%) 0.078 Cum Incidence of relapse (2-year) 28% (17-46%) 26% (17-41%) 0.858 EFS (2-year) 54% (38-69%) 38% (26-52%) 0.191 OS (2-year) 56% (40-72%) 47% (34-60%) 0.244 Outcomes . TAC-SIR . TAC-SIR-ATG . P-value . Median days (range) to ANC>500/\u00b5L 16 (10-29) 15 (9-24) 0.037 Median days (range) to platelets engraftment 12 (6-26) 15 (0-50) 0.005 Cum incidence acute GVHD (grade 2-4) (at 100 day) 67% (55-83%) 44% (33-59%) 0.055 Cum incidence acute GVHD (grade 3-4) (at 100-day) 16% (8-32%) 10% (5-21%) 0.347 Chronic moderate or severe (at 2-year) 38% (25-60%) 17% (10-30%) 0.086 Cum incidence of NRM (at 100-day) 12% (5-27%) 13% (7-25%) 0.078 Cum incidence of NRM (2-year) 17% (10-35%) 35% (24-50%) 0.078 Cum Incidence of relapse (2-year) 28% (17-46%) 26% (17-41%) 0.858 EFS (2-year) 54% (38-69%) 38% (26-52%) 0.191 OS (2-year) 56% (40-72%) 47% (34-60%) 0.244 View Large Disclosures Off Label Use: Sirolimus for GVHD prophylaxis. Perkins: PDL Biopharma: Research Funding. Falantes: Celgene: Honoraria. Valc\u00e1rcel: Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; GlaxoSmithKline: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau.",
    "topics": [
        "antithymoglobulin",
        "graft-versus-host disease",
        "hematopoietic stem cell transplantation",
        "human leukocyte antigens",
        "mismatch",
        "rapamycin",
        "tacrolimus",
        "teller acuity cards",
        "total arterial compliance",
        "trigeminal autonomic cephalalgias"
    ],
    "author_names": [
        "Mohamed A. Kharfan-Dabaja, MD",
        "Rocio Parody, MD",
        "Janelle Perkins, PharmD",
        "Oriana Lopez-Godino, MD",
        "Lucia Lopez-Corral, MD",
        "Lourdes Vazquez, MD",
        "Dolores Caballero, MD",
        "Jose Falantes, MD",
        "Jamie Shapiro, PharmD",
        "Guillermo Orti, MD",
        "Pere Barba, MD",
        "David Valc\u00e1rcel, MD PhD",
        "Alber Esquirol, MD",
        "Rodrigo Martino, MD PhD",
        "Jose Luis Pi\u00f1ana, MD",
        "Carlos Solano, MD",
        "Joseph A Pidala, MD, PhD",
        "Claudio Anasetti, MD",
        "Jose A. Perez-Simon, MD, PhD"
    ],
    "author_dict_list": [
        {
            "author_name": "Mohamed A. Kharfan-Dabaja, MD",
            "author_affiliations": [
                "Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL ",
                "Dept. of Oncologic Sciences, University of South Florida, Morsani College of Medicine, Tampa, FL "
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Rocio Parody, MD",
            "author_affiliations": [
                "Dept. of Hematology, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain "
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Janelle Perkins, PharmD",
            "author_affiliations": [
                "University of South Florida College of Pharmacy, Tampa, FL ",
                "Dept. of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL "
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Oriana Lopez-Godino, MD",
            "author_affiliations": [
                "Hospital Universitario de Salamanca, Salamanca, Spain "
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lucia Lopez-Corral, MD",
            "author_affiliations": [
                "Hospital Universitario de Salamanca, Salamanca, Spain "
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lourdes Vazquez, MD",
            "author_affiliations": [
                "Hospital Universitario de Salamanca, Salamanca, Spain "
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Dolores Caballero, MD",
            "author_affiliations": [
                "Hospital Universitario de Salamanca, Salamanca, Spain "
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose Falantes, MD",
            "author_affiliations": [
                "Department of Hematology, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain "
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jamie Shapiro, PharmD",
            "author_affiliations": [
                "Dept. of Pharmacy, Moffitt Cancer Center, Tampa, FL "
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Guillermo Orti, MD",
            "author_affiliations": [
                "Hospital Universitario Valld'Hebron, Barcelona, Spain "
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pere Barba, MD",
            "author_affiliations": [
                "Hospital Universitario Valld'Hebron, Barcelona, Spain "
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "David Valc\u00e1rcel, MD PhD",
            "author_affiliations": [
                "Hospital Vall d'Hebr\u00f3n, Barcelona, Spain "
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Alber Esquirol, MD",
            "author_affiliations": [
                "Hospital Santa Creu i Sant Pau, Barcelona, Spain "
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Rodrigo Martino, MD PhD",
            "author_affiliations": [
                "Hospital Santa Creu i Sant Pau, Barcelona, Spain "
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose Luis Pi\u00f1ana, MD",
            "author_affiliations": [
                "Hematology Department, Hospital Clinico de Valenci, Valencia, Spain "
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Carlos Solano, MD",
            "author_affiliations": [
                "Hospital Clinico de Valenci, Valencia, Spain"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Joseph A Pidala, MD, PhD",
            "author_affiliations": [
                "Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL "
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Claudio Anasetti, MD",
            "author_affiliations": [
                "Dept. of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL "
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Jose A. Perez-Simon, MD, PhD",
            "author_affiliations": [
                "Dept. of Hematology, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain "
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-06-01T18:39:23",
    "is_scraped": "1"
}